CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma (MM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03473496|
Recruitment Status : Terminated (After CAR-T treatment, the benefit is not significant, and it is difficult to enroll.)
First Posted : March 22, 2018
Last Update Posted : September 24, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Relapsed/Refractory Multiple Myeloma(MM)||Biological: CART therapy in Relapsed/Refractory multiple myeloma||Not Applicable|
Multiple myeloma（MM） is one of the most common malignant diseases in the blood system.There is still no cure for the disease which only control the development of the disease in various ways.
In recent years, the understanding of pathogenic molecular mechanism in MM , many new types of drugs can be used in the treatment of this disease, one of the most widely used is proteasome inhibitors and immune regulator.Hematopoietic stem cell transplantation has also been shown to improve complete remission rates and prolong patient survival.Combined with the advantages of multiple therapies, chimeric antigen receptor T cells (CAR-T) have gradually become one of the strongest and most powerful weapons against multiple myeloma.
CAR - T cells was taken in the form of genetic modification, and specific identified target antigen monoclonal antibody of single variable region (scFv) expression in T cell surface, and coupled with the activation of intracellular proliferation signal domain.
When scFv recognizes antigens expressed in malignant cells, it stimulates the activation signal of downstream T cells and produces specific killing effects. CAR-T therapy is one of revolutionary targeted immunotherapy.The efficacy of CAR-T cells for the treatment of acute B lymphocytic leukemia has been widely recognized, and several clinical trials have been reported in the treatment of multiple myeloma with CAR-T cells.Throughout registration of clinical trials and published research results, B-cell maturation antigen (BCMA) as one of targets , its effect is more significant than other molecules.As with BCMA antigens, cluster of differentiation 138(CD138), cluster of differentiation 56 (CD56) or cluster of differentiation 38(CD38) antigens are also highly expressed in multiple myeloma cells.With CD138 as the target for the treatment of CAR-T cells, several clinical studies have been registered, and the results show that some of them are effective.
In order to lay a foundation for the application of relapsed/refractory multiple myeloma patients with CAR-T therapy，objects are refractory/ relapsed patients with multiple myeloma,and plans to into the group of the number of cases in 50 cases.The main content is safety, efficacy and feasibility analysis of the CAR-T cells （single CAR-T or double CAR-T cells with BCMA、CD138、CD56 or CD38 ) in the treatment of refractory/relapsed multiple myeloma.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Prospective, Multi-center And Single-arm Clinical Study of Chimeric Antigen Receptor T(CAR-T) Cells Therapy in Relapsed/Refractory Multiple Myeloma|
|Actual Study Start Date :||March 1, 2018|
|Actual Primary Completion Date :||January 31, 2020|
|Actual Study Completion Date :||January 31, 2020|
Experimental: CART therapy in multiple myeloma
In order to assess the safety and validity of using CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
Biological: CART therapy in Relapsed/Refractory multiple myeloma
one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
- Adverse events that Are related to treatment [ Time Frame: 2 years ]Determine the toxicity profile of the BCMA/CD138/CD38/CD56-targeted CAR-T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0
- Estimate 2 year overall survival(OS) after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment [ Time Frame: 2 years ]To estimate 2 year overall survival(OS) after BCMA/CD138/CD38/CD56-CART infusion and sequential treatment with Relapsed/Refractory MM
- Estimate 2 year relapse rate after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment [ Time Frame: 2 years ]To estimate 2 year relapse rate after BCMA/CD138/CD38/CD56-CART infusion and sequential treatment with Relapsed/Refractory MM
- Estimate 2 year progression free survival after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment [ Time Frame: 2 years ]To estimate 2 year progression free survival after BCMA/CD138/CD38/CD56-CART infusion and sequential treatment with Relapsed/Refractory MM
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Relapsed/Refractory MM patients
- Cell phenotype is BCMA/CD138/CD38/CD56 positive (single or combined) ,and minimal residual disease (MRD) was positive(cytology, genetic testing)
- Estimated survival time is more than 3 months in multiple myeloma,and Karnofsky performance status(KPS) score is more than 60.
- No cytapheresis and cell separation contraindication.
- Hemoglobin is more than 80 gram per litre.
- The function of important organ was satisfied:(1)cardiac ultrasound indicated that cardiac ejection fractions is more than 50%（EF≥50%）, and the electrocardiogram showed no obvious abnormality;(2)Blood oxygen saturation is more than 90%（SpO2≥90%）;(3)Creatinine（Cr） is less than 2.5 times normal range;(4)Alanine transaminase（ALT） and glutamic-oxalacetic transaminase（AST）is less than 3 times normal range,and total bilirubin is less than 2 milligram per deciliter(TBil≤2.0mg/dL).
- After discussion by the expert group, the patient's condition was analyzed and combined with the general physical condition of the patient, the benefit of participating in the clinical trial was greater than the risk.
- Volunteered for this clinical trail and signed a consent form .
- Patients with high tumor burden or progression of disease need to control the progression of disease in order to decrease the tumor burden.
- Patients with active infection and fever.
- Patients' neutrophilic granulocyte has decreased more than 10 days,and is difficult to control after treatment.
- Patients are infected with fungus,bacteria or virus,and are difficult to control after treatment.
- Patients with infection of HIV or with actively infection of Hepatitis B Virus(HBV) or Hepatitis C Virus(HCV).
- Pregnant or lactating women.
- Patients with severe insufficient cardiac, pulmonary and hepatorenal functions.
- Patients had been treated with cell therapy but was invalid.After analyzing the patient's condition , the expert group think that the patient doesn't fit to attend the therapy of CART.
- The monoclonal antibodies of BCMA or CD38 are invalid for the patients who have used the drug.
- Any situation may do harm to the subjects or interfere the results.
- After allogeneic transplantation, patients are more than 3 degrees of acute Graft-Versus-Host disease(GVHD).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03473496
|Southern Medical University Zhujiang Hospital|
|Guangdong, Guangdong, China, 510000|
|Principal Investigator:||Yanjie He||Zhujiang Hospital|
|Responsible Party:||Zhujiang Hospital|
|Other Study ID Numbers:||
|First Posted:||March 22, 2018 Key Record Dates|
|Last Update Posted:||September 24, 2021|
|Last Verified:||September 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Blood Protein Disorders
Immune System Diseases